Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H21/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/167456ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION
WO 11.08.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2022/052417 Applicant F. HOFFMANN-LA ROCHE AG Inventor FUNDER, Erik
The present invention relates to enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity. The invention, in particular, relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention, in particular, relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
2.WO/2022/165838SYNTHESIS APPARATUS, SYNTHESIZER AND SYNTHESIS METHOD
WO 11.08.2022
Int.Class B01J 19/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
19Chemical, physical or physico-chemical processes in general; Their relevant apparatus
Appl.No PCT/CN2021/076015 Applicant BGI SHENZHEN Inventor HU, Dinglong
Provided is a synthesis apparatus for synthesizing biomacromolecules. The synthesis apparatus is used for synthesizing biomacromolecules, and comprises a feeding apparatus, a recognition apparatus, a reaction apparatus, a sorting apparatus and a transfer apparatus, wherein the feeding apparatus comprises a conveying assembly that is capable of conveying a plurality of biochips at the same time; the recognition apparatus is used for recognizing identifiers of the biochips on the conveying assembly and feeding back generated identification information to a control apparatus; the reaction apparatus comprises a plurality of reaction containers, the reaction containers being used for performing a synthesis reaction on the biochips; the sorting apparatus comprises a plurality of first sorting assemblies, which are located on a side face of a conveying apparatus and respectively correspond to the plurality of reaction containers, the plurality of first sorting assemblies being used for sorting, under the control of the control apparatus, the plurality of biochips located on the conveying assembly to the reaction containers corresponding to current synthesis reactions of the biochips; and the transfer apparatus is used for transferring the biochips in the reaction containers to the feeding apparatus. Further provided are a synthesizer and a synthesis method.
3.4039809COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
EP 10.08.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 21212946 Applicant ALNYLAM PHARMACEUTICALS INC Inventor QUERBES WILLIAM
The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HAO1 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.
4.4039278OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION
EP 10.08.2022
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
Appl.No 22162215 Applicant ALNYLAM PHARMACEUTICALS INC Inventor MANOHARAN MUTHIAH
The present invention relates to ligand conjugates of oligonucleotides (e.g., iRNA agents). The ligands are derived primarily from monosaccharides These conjugates are useful for the in vivo delivery of oligonucleotides.
5.4039690A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION
EP 10.08.2022
Int.Class C07F 9/6558
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9Compounds containing elements of Groups 5 or 15 of the Periodic System
02Phosphorus compounds
547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
6558containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
Appl.No 21210674 Applicant EISAI R&D MAN CO LTD Inventor ENDO ATSUSHI
We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs)
6.WO/2022/164978METHOD OF TREATING CORNEAL OPACITIES AND SCARRING
WO 04.08.2022
Int.Class A61P 27/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
Appl.No PCT/US2022/014019 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor CHAUHAN, Bharesh, Kumar
Provided herein are methods of treating corneal opacities in patients, such as neonates, comprising administering to the patient's eye or cornea a ZBTB7B and/or granulin polypeptide, and/or knocking down expression of HAS2 and/or HYAL1 in the patient's eye or cornea.
7.WO/2022/162153CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF
WO 04.08.2022
Int.Class C07H 15/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
Appl.No PCT/EP2022/052067 Applicant E-THERAPEUTICS PLC Inventor MORTAZAVI, Ahmad Ali
The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.
8.WO/2022/162154CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF
WO 04.08.2022
Int.Class C07H 15/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
Appl.No PCT/EP2022/052069 Applicant E-THERAPEUTICS PLC Inventor MORTAZAVI, Ahmad Ali
The present invention provides novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.
9.WO/2022/162155NUCLEIC ACIDS CONTAINING ABASIC NUCLEOTIDES
WO 04.08.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2022/052070 Applicant E-THERAPEUTICS PLC Inventor MORTAZAVI, Ahmad Ali
The present invention relates to nucleic acid molecules for use in the treatment or prevention of disease.
10.20220243252ISOTOPE MODIFIED NUCLEOTIDES FOR DNA DATA STORAGE
US 04.08.2022
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No 17308837 Applicant Seagate Technology LLC Inventor Eric K. WADLEIGH

Methods of encoding data in a DNA strand or an RNA strand. In one method, a first nucleotide has a first bit pattern assigned thereto, and a second modified nucleotide has a second bit pattern assigned thereto different than the first bit pattern. The second modified nucleotide is different from the first nucleotide in that the second nucleotide is either isotope-modified, comprising at least one isotope of one of carbon, nitrogen, oxygen or hydrogen, or otherwise-modified, such as with a different atom in a cyclic position or with a ligated metal ion or atom. Data, in the form of bits, can be stored on any molecule that can be isotope- or otherwise modified.